Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services
inspiris.com

See what CB Insights has to offer

Founded Year

1998

Stage

Acquired | Acquired

Total Raised

$24.68M

About Inspiris

Inspiris is a healthcare management organization that aims to provide enhanced health and social services to institutionalized Medicare beneficiaries. The company provides care and care management services within diverse Medicare, Medicaid and commercial populations that result in meaningful improvements in clinical quality, reductions in utilization (acute admits/re-admits, ER visits, skilled days, etc.), improved risk scores and member satisfaction.In March 2011, Inspiris was acquired by OptumHealth, a subsidiary of UnitedHealth Group. The valuation of Inspiris was undisclosed. Other terms of the deal were not released.

Inspiris Headquarter Location

Two Creekside Crossing 10 Cadillac Drive Suite 350

Brentwood, Tennessee, 37027,

United States

888-315-5442

Latest Inspiris News

Edwards' INSPIRIS RESILIA Valve Receives FDA Approval

Jul 7, 2017

News | July 5, 2017 Edwards' INSPIRIS RESILIA Valve Receives FDA Approval Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, recently announced it received U.S. Food and Drug Administration (FDA) approval for its INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8124551-edwards-lifesciences-inspiris-valve-fda-approval/ "The INSPIRIS valve sets a new benchmark for surgical aortic valve replacement, providing patients, particularly those with active lifestyles, with a resilient tissue valve that is built on Edwards' legacy of excellence in heart valve innovations," said John D. Puskas, MD, MSc, FACC, FACS, professor of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, chairman, Department of Cardiothoracic Surgery, Mount Sinai Saint Luke's, Mount Sinai Beth Israel and Mount Sinai West (Roosevelt) and national principal investigator of the COMMENCE pivotal trial, an FDA premarket approval study. Joseph Bavaria, MD, Roberts-Measey professor and vice chief of cardiovascular surgery at the University of Pennsylvania and the top implanter in the COMMENCE pivotal trial, said, "With the addition of VFit technology, featuring the unique expandable design feature, the INSPIRIS valve provides an ideal foundation for heart valve patients, both now and in the future." The INSPIRIS valve features three differentiating elements: RESILIA tissue, a breakthrough tissue technology that delivers the combination of enhanced anti-calcification properties, improved sustained hemodynamic performance and dry storage; A first-of-its-kind expandable frame, VFit technology also incorporates fluoroscopically visible size markers and is designed for potential future valve-in-valve procedures; A trusted valve platform built on the proven performance of the Carpentier-Edwards PERIMOUNT valve design, which has more than 20 years of published clinical durability. Approval of the INSPIRIS valve is supported by the COMMENCE pivotal trial. Published in the European Journal of Cardio-Thoracic Surgery, two-year data of 689 patients from the COMMENCE trial showed no cases of structural valve deterioration, valve thrombosis or nonstructural valve dysfunction. In addition, the European RESILIA tissue feasibility study, which initiated enrollment in 2011, underscores the safety and effectiveness of the RESILIA tissue. Four-year results from the European feasibility study will be presented at the 31st European Association for Cardio-Thoracic Surgery's (EACTS) annual meeting in October. "Building on Edwards' 40 years of leadership in tissue valve technology, the INSPIRIS valve featuring RESILIA tissue has been indevelopment for more than a decade and may be uniquely suited for future valve-in-valve procedures," said Bernard Zovighian, Edwards' corporate vice president, surgical heart valve therapy. "In partnership with surgeons, Edwards is committed to continually developing transformative surgical innovations that benefit patients. "   Plans are underway for a full U.S. launch of the INSPIRIS valve in early 2018. The valve became commercially available in Europeearlier this year. About Edwards Lifesciences Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com. SOURCE: Edwards Lifesciences Corporation Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy . YOU MAY ALSO LIKE...

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inspiris

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inspiris is included in 1 Expert Collection, including Smart Money VCs (2017-2019).

S

Smart Money VCs (2017-2019)

6,297 items

We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.